<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">26978871</PMID>
      <DateCompleted>
        <Year>2016</Year>
        <Month>04</Month>
        <Day>15</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2018</Year>
        <Month>11</Month>
        <Day>13</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">2457-4325</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>59</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2015</Year>
              <Season>Apr-Jun</Season>
            </PubDate>
          </JournalIssue>
          <Title>Romanian journal of ophthalmology</Title>
          <ISOAbbreviation>Rom J Ophthalmol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>GRAVES OPHTHALMOPATHY--TERAPEUTICAL ALTERNATIVES.</ArticleTitle>
        <Pagination>
          <StartPage>103</StartPage>
          <EndPage>106</EndPage>
          <MedlinePgn>103-6</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Graves disease associates thyroid and non-thyroid symptoms and signs with autoimmune pathogeny, including the ophthalmopathy. The treatment of Graves ophthalmopathy consists of medical immunosuppressive therapy, retrobulbar injections and general treatment. Recently, Somatostatin injections have proved their efficiency.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Jurja</LastName>
            <ForeName>Sanda</ForeName>
            <Initials>S</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D003160">Comparative Study</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Rom J Ophthalmol</MedlineTA>
        <NlmUniqueID>101677459</NlmUniqueID>
        <ISSNLinking>2457-4325</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D005938">Glucocorticoids</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>51110-01-1</RegistryNumber>
          <NameOfSubstance UI="D013004">Somatostatin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>VB0R961HZT</RegistryNumber>
          <NameOfSubstance UI="D011241">Prednisone</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005938" MajorTopicYN="N">Glucocorticoids</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049970" MajorTopicYN="N">Graves Ophthalmopathy</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007279" MajorTopicYN="N">Injections, Subcutaneous</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011241" MajorTopicYN="N">Prednisone</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013004" MajorTopicYN="N">Somatostatin</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2016</Year>
          <Month>3</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2016</Year>
          <Month>3</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2016</Year>
          <Month>4</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">26978871</ArticleId>
        <ArticleId IdType="pmc">PMC5712926</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Witmar M, Wiersinga WM.  Graves Ophthalmopathy. Amsterdam: Thyroid International no. 3; 1997. </Citation>
        </Reference>
        <Reference>
          <Citation>Wiersinga WM.  Advances in Medical Therapy of Thyroid Associated Ophthalmopathy. Amsterdam: Med. Ed.; 1996. </Citation>
        </Reference>
        <Reference>
          <Citation>Dumitrache C.  Endocrinologie – Mica Encicopedie. Ed. National; 1998. </Citation>
        </Reference>
        <Reference>
          <Citation>Bahnv RS.  Grave’s Disease. A comprehensive Guide for Clinicians. Ed. Springer; 2015. </Citation>
        </Reference>
        <Reference>
          <Citation>Croxon MS, Hall TD, Nicoloff JT. Combination Drug Therapy for Treatment of Hyperthyroid Grave’s Disease. doi:  http://dx.doi.org/10.1210/jcem-45-4-623 </Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jcem-45-4-623</ArticleId>
            <ArticleId IdType="pubmed">578804</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Groves N. Reviewed by Sullivan TJ. MBBS - Matching steroid therapy, thyroid eye disease severity key to response. Ophthalmology Times. 2015</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
